27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
- AstraZeneca plc (NASDAQ:AZN) scrapped its license agreement with Aridis Pharmaceuticals Inc (NASDAQ:ARDS).
- With the license terminated for AR-320 (suvratoxumab), the ongoing AR-320-003 Phase 3 clinical study must be put on hold, the company said in an SEC filing.
- The SAATELLITE-2 trial enrolled the first patient in September 2022, and was expected to enroll 564 intubated and ventilated patients.
- The companies entered the agreement in July 2021, under which Aridis said it would make an upfront payment of $11 million to AstraZeneca and dish out up to $115 million more for development and sales milestones tiered royalties on any potential product sales.
- The trial was partly funded by the European Commission's Innovative Medicines Initiative, which contributed up to €25 million to the study.
- In January, Aridis' other late-stage study, AR-301-002 Phase 3 study of AR-301 combined with antibiotics, failed to meet the primary endpoint of increasing the clinical cure rate at day 21 compared to antibiotics alone.
- The clinical cure rate at day 21 was 68.9% for AR-301 plus antibiotics versus 57.6% with antibiotics alone. There was an 11.3% difference between the arms. The result was not statistically significant (p=0.23).
- Price Action: ARDS shares are down 0.97% at $0.39 on the last check Wednesday.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!